BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 38555023)

  • 1. Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Khatua K; Alugubelli YR; Yang KS; Vulupala VR; Blankenship LR; Coleman D; Atla S; Chaki SP; Geng ZZ; Ma XR; Xiao J; Chen PH; Cho CD; Sharma S; Vatansever EC; Ma Y; Yu G; Neuman BW; Xu S; Liu WR
    Antiviral Res; 2024 May; 225():105874. PubMed ID: 38555023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Azapeptide Platform in Conjunction with Covalent Warheads to Uncover High-Potency Inhibitors for SARS-CoV-2 Main Protease.
    Khatua K; Alugubelli YR; Yang KS; Vulupala VR; Blankenship LR; Coleman DD; Atla S; Chaki SP; Geng ZZ; Ma XR; Xiao J; Chen PC; Cho CD; Vatansever EC; Ma Y; Yu G; Neuman BW; Xu S; Liu WR
    bioRxiv; 2023 Apr; ():. PubMed ID: 37090597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
    La Monica G; Bono A; Lauria A; Martorana A
    J Med Chem; 2022 Oct; 65(19):12500-12534. PubMed ID: 36169610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
    Gao S; Song L; Claff T; Woodson M; Sylvester K; Jing L; Weiße RH; Cheng Y; Sträter N; Schäkel L; Gütschow M; Ye B; Yang M; Zhang T; Kang D; Toth K; Tavis J; Tollefson AE; Müller CE; Zhan P; Liu X
    J Med Chem; 2022 Dec; 65(24):16902-16917. PubMed ID: 36475694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
    Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
    Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
    Yu W; Zhao Y; Ye H; Wu N; Liao Y; Chen N; Li Z; Wan N; Hao H; Yan H; Xiao Y; Lai M
    J Med Chem; 2022 Dec; 65(24):16252-16267. PubMed ID: 36503248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
    Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.
    Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI
    Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Inhibitors of Main Protease (M
    Mondal S; Chen Y; Lockbaum GJ; Sen S; Chaudhuri S; Reyes AC; Lee JM; Kaur AN; Sultana N; Cameron MD; Shaffer SA; Schiffer CA; Fitzgerald KA; Thompson PR
    J Am Chem Soc; 2022 Nov; 144(46):21035-21045. PubMed ID: 36356199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
    Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR
    ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
    Ma Y; Yang KS; Geng ZZ; Alugubelli YR; Shaabani N; Vatansever EC; Ma XR; Cho CC; Khatua K; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114570. PubMed ID: 35779291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diphenyl Diselenide and SARS-CoV-2:
    Omage FB; Madabeni A; Tucci AR; Nogara PA; Bortoli M; Rosa ADS; Neuza Dos Santos Ferreira V; Teixeira Rocha JB; Miranda MD; Orian L
    J Chem Inf Model; 2023 Apr; 63(7):2226-2239. PubMed ID: 36952618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.
    Pillaiyar T; Flury P; Krüger N; Su H; Schäkel L; Barbosa Da Silva E; Eppler O; Kronenberger T; Nie T; Luedtke S; Rocha C; Sylvester K; Petry MRI; McKerrow JH; Poso A; Pöhlmann S; Gütschow M; O'Donoghue AJ; Xu Y; Müller CE; Laufer SA
    J Med Chem; 2022 Jul; 65(13):9376-9395. PubMed ID: 35709506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
    Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease.
    Su H; Yao S; Zhao W; Zhang Y; Liu J; Shao Q; Wang Q; Li M; Xie H; Shang W; Ke C; Feng L; Jiang X; Shen J; Xiao G; Jiang H; Zhang L; Ye Y; Xu Y
    Nat Commun; 2021 Jun; 12(1):3623. PubMed ID: 34131140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
    Hattori SI; Higshi-Kuwata N; Raghavaiah J; Das D; Bulut H; Davis DA; Takamatsu Y; Matsuda K; Takamune N; Kishimoto N; Okamura T; Misumi S; Yarchoan R; Maeda K; Ghosh AK; Mitsuya H
    mBio; 2020 Aug; 11(4):. PubMed ID: 32820005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.